ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer

Tang, Bin; Wu, Min; Zhang, Lin; Jian, Shuyi; Lv, Shiyi; Lin, Tongyuan; Zhu, Shuangshuang; Liu, Layang; Wang, Yixue; Yi, Zhengfang*; Jiang, Feiyun*2
Frontiers in Oncology2023-4-18DOI: 10.3389/fonc.2023.1154073
2被引5阅读
引用收藏
分享

摘要

IntroductionDue to the difficulty of early diagnosis, nearly 70% of ovarian cancer patients are first diagnosed at an advanced stage. Thus, improving current treatment strategies is of great significance for ovarian cancer patients. Fast-developing poly (ADP-ribose) polymerases inhibitors (PARPis) have been beneficial in the treatment of ovarian cancer at different stages of the disease, but PARPis have serious side effects and can result in drug resistance. Using PARPis in combination with other drug therapies could improve the efficacy of PRAPis.In this study, we identified Disulfiram as a potential therapeutic candidate through drug screening and tested its use in combination with PARPis. MethodsCytotoxicity tests and colony formation experiments showed that the combination of Disulfiram and PARPis decreased the viability of ovarian cancer cells ResultsThe combination of PARPis with Disulfiram also significantly increased the expression of DNA damage index gH2AX and induced more PARP cleavage. In addition, Disulfiram inhibited the expression of genes associated with the DNA damage repair pathway, indicating that Disulfiram functions through the DNA repair pathway. DiscussionBased on these findings, we propose that Disulfiram reinforces PARPis activity in ovarian cancer cells by improving drug sensitivity. The combined use of Disulfiram and PARPis provides a novel treatment strategy for patients with ovarian cancer.

学科与关键词

关键词
poly (ADP-ribose) polymerase inhibitorsovarian cancerdrug combinationdisulfiramDNA damage repair
相关
加载中…
  • Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death
    Guo, Fang; Yang, Zhi; Sehouli, Jalid; Kaufmann, Andreas M.*Current Oncology, 2022, 29(4): 2808-2822.被引 9
  • Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer
    Tzu-Ting Huang; Erika J. Lampert; Cynthia Coots; Jung-Min LeeCancer Treatment Reviews, 2020, 86.
  • Quantitative proteomics analysis reveals novel insights into mechanisms of action of disulfiram (DSF)
    Zheng, Peng*; Liu, Chenglinzi; Wu, Yaoqin; Xu, Ruifeng; Chen, Ying; Hu, Fan; Chen, Zhuo*; Zhang, Tongcun*Proteomics Clinical Applications, 2022, 16(1): e2100031.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2023-04-18
卷期
第 13 卷
页码
1154073
DOI
10.3389/fonc.2023.1154073
成果收录
SCIE

作者

  • T

    Tang, Bin (第一作者)

    2

  • W

    Wu, Min

查看全部 11 位作者收起作者
  • Z

    Zhang, Lin

  • J

    Jian, Shuyi

  • L

    Lv, Shiyi

  • L

    Lin, Tongyuan

    2

  • Z

    Zhu, Shuangshuang

  • L

    Liu, Layang

  • W

    Wang, Yixue

  • Y

    Yi, Zhengfang (通讯)

  • J

    Jiang, Feiyun (通讯)

    2

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417